Unscrambling hepatitis C virus-host interactions

Nature

Volumn 436, Issue 7053, 2005, Pages 930-932

  Chisari, Francis V ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL ORGANS; CELL CULTURE; DRUG PRODUCTS; MATHEMATICAL MODELS; TUMORS;

HEPATITIS C; INFECTIONS; LIVER;

VIRUSES;

ALPHA INTERFERON; ANTIVIRUS AGENT; HEPATITIS C VACCINE; PEGINTERFERON; RECOMBINANT VACCINE; RIBAVIRIN;

HEPATITIS;

ANTIVIRAL ACTIVITY; CANCER; CELL CULTURE; GENOTYPE; HEPATITIS C; HUMAN; INNATE IMMUNITY; LIFE CYCLE; LIVER FAILURE; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; REVIEW; VIRAL GENETICS; VIRUS CELL INTERACTION;

ANIMALS; HEPACIVIRUS; HEPATITIS C; HOST-PARASITE RELATIONS; HUMANS; VIRAL HEPATITIS VACCINES;

ANIMALIA; HEPATITIS C VIRUS;

EID: 23944481107     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/nature04076     Document Type: Review

References (39)

1. Hoofnagle, J. H. Course and outcome of hepatitis C. Hepatology 36, S21-S29 (2002).
2. Alter, H. J. & Seeff, L. B. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin. Liver Dis. 20, 17-35 (2000).
3. Alter, M. J. Epidemiology of hepatitis C. Eur. J. Gastroenterol. Hepatol. 8, 319-323 (1996).
4. Alter, M. J. Epidemiology of hepatitis C. Hepatology 26, 62S-65S (1997).
5. Alter, M. J. Hepatitis C virus infection in the United States. J. Hepatol. 31 (Suppl. 1), 88-91 (1999).
6. Alter, M. J. Prevention of spread of hepatitis C. Hepatology 36, S93-S98 (2002).
7. Spaulding, A., Greene, C., Davidson, K., Schneidermann, M. & Rich, J. Hepatitis C in state correctional facilities. Prev. Med. 28, 92-100 (1999).
8. Sulkowski, M. S., Mast, E. E., Seeff, L. B. & Thomas, D. L. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin. Infect. Dis. 30 (Suppl. 1), S77-S84 (2000).
9. Choo, Q. L. et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244, 359-362 (1989).
10. Sarnow, P. Viral internal ribosome entry site elements: novel ribosome-RNA complexes and roles in viral pathogenesis. J. Virol. 77, 2801-2806 (2003).
11. Lohmann, V., Koch, J. O. & Bartenschlager, R. Processing pathways of the hepatitis C virus proteins. J. Hepatol. 24, 11-19 (1996).
12. Penin, F., Dubuisson, J., Rey, F. A., Moradpour, D. & Pawlotsky, J. M. Structural biology of hepatitis C virus. Hepatology 39, 5-19 (2004).
13. Moradpour, D. et al. Membrane association of the RNA-dependent RNA polymerase is essential for hepatitis C virus RNA replication. J. Virol. 78, 13278-13284 (2004).
14. Samuel, C. E. Antiviral actions of interferons. Clin. Microbiol. Rev. 14, 778-809 (2001).
15. Yoneyama, M. et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nature Immunol. 5, 730-737 (2004).
16. Bartenschlager, R. Hepatitis C virus replicons: potential role for drug development. Nature Rev. Drug Discov. 1, 911-916 (2002).
17. Zhong, J. et al. Robust hepatitis C virus infection in vitro. Proc. Natl Acad. Sci. USA 102, 9294-9299 (2005).
18. Lindenbach, B. D. et al. Complete replication of hepatitis C virus in cell culture. Science 309, 623-626 (2005).
19. Wakita, T. et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nature Med. 11, 791-796 (2005).
20. Kato, T. et al. Sequence analysis of hepatitis C virus isolated from a fulminant hepatitis patient. J. Med. Virol. 64, 334-339 (2001).
21. Kato, T. et al. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 125, 1808-1817 (2003).
22. Wieland, S. F. & Chisari, F. V. Stealth and cunning: hepatitis B and hepatitis C. J. Virol. 79, 9369-9380 (2005).
23. Rehermann, B. & Nascimbeni, M. Immunology of hepatitis B virus and hepatitis C virus infection. Nature Rev. Immunol. 5, 215-229 (2005).
24. Bigger, C. B. et al. Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J. Virol. 78, 13779-13792 (2004).
25. Shoukry, N. H., Cawthon, A. G. & Walker, C. M. Cell-mediated immunity and the outcome of hepatitis C virus infection. Annu. Rev. Microbiol. 58, 391-424 (2004).
26. Neumann, A. U. et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 282, 103-107 (1998).
27. Lanford, R. E. & Bigger, C. Advances in model systems for hepatitis C virus research. Virology 293, 1-9 (2002).
28. Foy, E. et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 300, 1145-1148 (2003).
29. Foy, E. et al. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc. Natl Acad. Sci. USA 102, 2986-2991 (2005).
30. Mondelli, M. U. et al. Hypervariable region 1 of hepatitis C virus: immunological decoy or biologically relevant domain? Antiviral Res. 52, 153-159 (2001).
31. Bowen, D. G. & Walker, C. M. Mutational escape from CD8+ T cell immunity: HCV evolution, from chimpanzees to man. J. Exp. Med. 201, 1709-1714 (2005).
32. Meyer-Olson, D. et al. Limited T cell receptor diversity of HCV-specific T cell responses is associated with CTL escape. J. Exp. Med. 200, 307-319 (2004).
33. McHutchison, J. G. & Fried, M. W. Current therapy for hepatitis C: pegylated interferon and ribavirin. Clin. Liver Dis. 7, 149-161 (2003).
34. Pawlotsky, J. M. Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C. Antiviral Res. 59, 1-11 (2003).
35. Strader, D. B., Wright, T., Thomas, D. L. & Seeff, L. B. Diagnosis, management, and treatment of hepatitis C. Hepatology 39, 1147-1171 (2004).
36. Lamarre, D. et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426, 186-189 (2003).
37. Nevens, F. et al. A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology 38, 1289-1296 (2003).
38. Shimizu, Y. K. et al. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J. Virol. 68, 1494-1500 (1994).
39. Bassett, S. E. et al. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology 33, 1479-1487 (2001).